A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
about
Entecavir for chronic hepatitis BEntecavir for chronic hepatitis BTiopronin for chronic hepatitis BEntecavir for chronic hepatitis BTargeted DNA mutagenesis for the cure of chronic viral infectionsThe Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-AnalysisKASL clinical practice guidelines: management of chronic hepatitis BHepatitis B virus therapy: What's the future holding for us?The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsAntiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonCurrent and future directions for treating hepatitis B virus infectionDoes antiviral therapy reduce complications of cirrhosis?Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcomeHepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawalManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesAntiviral therapy for chronic hepatitis B in ChinaThe Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis BManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsThe importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysisDirect acting antivirals for the treatment of chronic viral hepatitisSeroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis BNucleoside/nucleotide analogues in the treatment of chronic hepatitis BPredictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approachPharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and MiceApproved Antiviral Drugs over the Past 50 YearsMolecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPKSubstitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug ResistanceCost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaThe Molecular Mechanisms of the Antibacterial Effect of Picosecond Laser Generated Silver Nanoparticles and Their Toxicity to Human CellsA novel estimation of the relative economic value in terms of different chronic hepatitis B treatment optionsAnalysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countriesSafety and efficacy of telbivudine for the treatment of chronic hepatitis BHepatitis B virus and its sexually transmitted infection - an update.Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Recent advances in micro/nanotechnologies for global control of hepatitis B infectionThe use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients.Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentImpact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.
P2860
Q24194997-237C51FA-A0F6-451C-9900-95EEA1744CE9Q24195119-F98CCBCE-E05A-4CCD-810C-6C995A21F819Q24244433-8B0DB8C3-A9E4-41FD-BCF3-176FA67313C9Q24244842-C08963AC-C631-4A87-9D88-9111CECBE90EQ24620150-A13D7218-2CE3-46CE-BF0E-1A0C9B516B07Q26752443-14D8B2D8-AB14-464E-91C7-B0B6DE23BF3BQ26752475-AD7A635F-A2F5-4624-AA06-42A7F57E7C57Q26774198-7798F498-31B9-479C-B7CA-33168F341096Q26781795-EBF80C3E-6B27-4CA7-AE7F-09E1C9D8ED76Q26830435-BF6DC654-884C-47E6-A79D-C101882D9B89Q26851240-CAF8AD56-5DE7-4899-A899-471626138223Q26851410-91478E23-A244-43F4-8006-10CB5089EE4CQ26859121-93063797-CEA5-4681-94FD-87F6AE933BEDQ26995814-5A873D60-A721-4C9D-9EDB-783E27F6B216Q27000080-3D9D964E-2BA3-4120-B3FD-3DCF3D48F91EQ27006557-F6C548F2-D43D-4DBE-941C-1CA91794EAACQ27007019-FB46B1E3-F7A1-4B81-BB4D-E2665E23EB60Q27008984-41F9F749-A6F6-4137-8946-C1C3886F305FQ27016075-F83B8CED-0A78-406D-87CD-43E99F56EBCEQ27022216-70BDDB46-BE86-4520-9061-3DC14E54AF87Q27023737-E20B5C48-5D0D-4D2F-8836-B7798313A767Q27030828-5996E7CB-A71C-4585-A7A5-3C63A8196B4FQ27324340-B8DF7961-B4AD-428E-BBC6-31DC11CE3DD6Q27488385-906E1B0F-3E5E-4F64-AC74-D7AA6275AB6AQ27755387-391D1A0F-C9FA-4010-8953-1DA00D0182B3Q28384866-0559C469-8705-4C56-88C4-492D872FCA73Q28547647-246D2FF8-4FE3-4529-B3A6-78BFEB045233Q28550643-C89203B2-75DB-43C8-AC53-CD802217312BQ28553763-1631FD56-BFAE-4FC9-ACCF-0A146E0415A8Q28704122-C40FFB53-CE7D-4561-9EAF-CAD45DC2FD5BQ28830093-0836C582-9D43-4A8D-AD03-AC6AE69E17E3Q28972486-A4CE7764-9445-4F01-85EE-3F03A7E7058DQ30235028-4B697800-3F62-4B44-B2B3-D980B396BB72Q30248818-785B9FAE-18E6-41B4-956D-E6D3A6C3A224Q30391932-945AE211-E19B-4843-BAB8-CBD970D18035Q30394611-97215512-D1BA-4193-AA58-B339CD07253CQ30586377-13F797F5-1A97-4C0F-A326-E934BCD02AF5Q30829485-CE9A3D26-1B5F-4E6C-B1DA-0FD2935D4252Q33267067-D3C3F28A-789B-4985-9201-F0848C142A5AQ33370720-FAFB4815-11C2-425F-878A-42B7EB24BD8B
P2860
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
@en
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
@nl
type
label
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
@en
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
@nl
prefLabel
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
@en
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
@nl
P2093
P356
P1476
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
@en
P2093
Adrian Gadano
Anna S Lok
Anne Cross
BEHoLD AI463022 Study Group
David Apelian
Deborah DeHertogh
José Sollano
Kwang-Hyub Han
Richard Colonno
P304
P356
10.1056/NEJMOA051285
P407
P50
P577
2006-03-01T00:00:00Z